Status:
COMPLETED
A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy
Lead Sponsor:
Bayside Health
Conditions:
Allergic Rhinitis
Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Allergic diseases represent a major health issue worldwide. Mainstay treatment is allergen avoidance and pharmacotherapy for symptom relief. Allergen immunotherapy offers the advantages of specific tr...
Eligibility Criteria
Inclusion
- allergic rhinitis and/or
- mild stable asthma
- house dust mite allergic
- positive HDM-specific IgE as determined by skin prick test (wheal diameter \>6 mm to D. pteronyssinus) or CAP-Pharmacia score \> 2
Exclusion
- Immunodeficiency diseases
- Severe or uncontrolled asthma
- Previous immunotherapy with House dust mite (HDM) extract within the last five years or ongoing immunotherapy with HDM or other allergens
- Continuous oral corticosteroids
- Subjects on treatment with beta-blockers
- Pregnant women
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00250263
Start Date
November 1 2005
End Date
December 1 2008
Last Update
February 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Alfred Hospital. Department of Allergy Immunology & Respiratory Medicine
Melbourne, Victoria, Australia, 3181